Letrozol Teva

Letrozole, the active ingredient in Letrozol Teva, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the management of hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Teva is an aromatase inhibitor used in the treatment of hormone‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to slow tumor growth. - Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer (postmenopausal): helps prevent disease recurrence. - Advanced or metastatic hormone receptor‑positive breast cancer (postmenopausal): provides disease control when other endocrine therapies are unsuitable.

Adverse reactions may occur with letrozole therapy and are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aches affecting mobility. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: tension‑type or throbbing pain. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, hepatic failure. - Bone fractures: increased risk due to reduced estrogen. - Pulmonary embolism: sudden shortness of breath, chest pain. - Severe allergic reactions: rash, swelling, anaphylaxis. - Elevated cholesterol: significant rise in LDL levels.

Patients should be monitored for specific safety considerations before and during letrozole therapy. - Bone health monitoring: assess bone mineral density regularly. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: check lipid profile and blood pressure. - Drug interaction review: verify concomitant medications for potential interactions. - Pregnancy and lactation warning: avoid use in pregnant or breastfeeding women. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect. - Tamoxifen: concurrent use can diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of bone loss. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring. - Glucocorticoids: may enhance risk of osteoporosis when combined with letrozole.